Selumetinib
- Generic Name
- Selumetinib
- Brand Names
- Koselugo
- Drug Type
- Small Molecule
- Chemical Formula
- C17H15BrClFN4O3
- CAS Number
- 606143-52-6
- Unique Ingredient Identifier
- 6UH91I579U
- Background
Activation of the Raf-MEK-ERK signaling pathway is known to be implemented in several types of malignancies, thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway.
...
- Indication
Although selumetinib has been investigated for the treatment of several types of cancer, it is currently only indicated for the treatment of neurofibromatosis type 1 (NF1) in patients β₯2 years who have symptomatic, inoperable plexiform neurofibromas (PN).
- Associated Conditions
- Neurofibromatosis, type 1 (von Recklinghausen's disease)
- Associated Therapies
- -
Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy
- First Posted Date
- 2010-07-12
- Last Posted Date
- 2019-05-15
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 46
- Registration Number
- NCT01160718
- Locations
- π¨π
Kantonsspital Aarau, Aarau, Switzerland
π¨πKantonsspital Baden, Baden, Switzerland
π¨πCity Hospital Triemli, Zurich, Switzerland
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
- Conditions
- Interventions
- First Posted Date
- 2010-06-14
- Last Posted Date
- 2017-07-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 120
- Registration Number
- NCT01143402
- Locations
- π¨π¦
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
πΊπΈMount Sinai Medical Center, Miami Beach, Florida, United States
πΊπΈEmory University/Winship Cancer Institute, Atlanta, Georgia, United States
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
- First Posted Date
- 2010-03-18
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 220
- Registration Number
- NCT01089101
- Locations
- πΊπΈ
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
πΊπΈChildren's Hospital Los Angeles, Los Angeles, California, United States
πΊπΈLucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2010-03-11
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 37
- Registration Number
- NCT01085214
- Locations
- πΊπΈ
Billings Clinic Cancer Center, Billings, Montana, United States
πΊπΈUniversity of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
πΊπΈVirginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States
Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2010-02-03
- Last Posted Date
- 2016-01-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT01061749
- Locations
- πΊπΈ
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 54
- Registration Number
- NCT01011933
- Locations
- πΊπΈ
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
πΊπΈSmilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States
πΊπΈRush University Medical Center, Chicago, Illinois, United States
Selumetinib in Cancers With BRAF Mutations
- First Posted Date
- 2009-04-27
- Last Posted Date
- 2016-01-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 28
- Registration Number
- NCT00888134
- Locations
- πΊπΈ
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
πΊπΈMassachusetts General Hospital, Charlestown, Massachusetts, United States
πΊπΈMemorial Sloan-Kettering Cancer Center, New York, New York, United States
MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma
- Conditions
- Interventions
- First Posted Date
- 2009-03-20
- Last Posted Date
- 2015-08-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 167
- Registration Number
- NCT00866177
- Locations
- πΊπΈ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2014-05-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 19
- Registration Number
- NCT00604721
- Locations
- πΊπΈ
Emory University, Atlanta, Georgia, United States
πΊπΈArthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
πΊπΈH. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2008-01-09
- Last Posted Date
- 2015-08-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 47
- Registration Number
- NCT00588809
- Locations
- πΊπΈ
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.